Drug intelligence / Profile preview

acetyl-DL-leucine

Development stage
Phase 3
Lead developer
IntraBio
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Acetyl-DL-leucine is a racemic (DL) mixture of the acetylated derivative of the amino acid leucine. It has been used since the 1950s, particularly in France, for symptomatic treatment of acute vestibular vertigo and dizziness. The compound is also studied for its neuroprotective properties and potential benefits in neurological disorders, including Niemann-Pick disease type C and cerebellar ataxia. Its mechanism of action is not fully understood but may involve restoration of membrane potential in injured vestibular neurons via interaction with membrane phospholipids, inhibition of mTORC1 to promote autophagy, enhancement of glucose utilization in brain cells, and balancing pH by facilitating lactate removal from neurons[3][4][5]. It does not bind or block LAT1 transporters[4]. Acetyl-DL-leucine is also used as a cognitive enhancer in dietary supplements and has applications in veterinary medicine[3].

Brand names
Tanganil
Other names
acetylleucineN-acetylleucineAcetileucinaAcetylleucinumAC-DL-LEU-OH
02

Targets

SLC16A1 (Mitochondrial Pyruvate Carrier)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on acetyl-DL-leucine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetyl-DL-leucine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call